Advertisement

Document › Details
Memo Therapeutics AG. (2/1/19). "Press Release: Memo Therapeutics Announces the Development of a Droplet Sorter Enabling Functional Antibody Screening in a High-Throughput Format".
This novel microfluidic droplet sorter will be deployed downstream of the MemoMAB antibody repertoire biobanking platform to enable functional screening in high througput format with a series of functional assays such as:
Cell-binding
Virus-neutralization
Identification of agonistic/antagonistic antibodies
ADCC assays
“This is a major step in the technology development at Memo since we are now able to directly screen antibody repertoire libraries from rare patients or immunized animals for antibodies with the desired functional activity in a single day. “ says Dr. Christoph Esslinger, CSO.
Dr. Karsten Fischer, CEO, comments: “Having such a tool at hand will enable us to pick the optimal antibody development candidates out of diverse repertoires for our own pipeline and attract high-profile partnerships with pharmaceutical companies.”
On the coprorate side, Memo has followed the planned trajectory and has moved its premises to State-of-the-art laboratories at Schlieren and launched a new corporate design including a new web site that can be visited at: http://www.memo-therapeutics.com
About Memo
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology.
Record changed: 2023-06-05 |
Advertisement

More documents for Memo Therapeutics AG (MTx)
- [1] Memo Therapeutics AG. (5/7/24). "Press Release: Memo Therapeutics Increases Series C Financing to CHF 45 Million". Schlieren....
- [2] Memo Therapeutics AG. (11/16/23). "Press Release: Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer". Schlieren....
- [3] Memo Therapeutics AG. (11/02/23). "Press Release: Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients". Schlieren....
- [4] Memo Therapeutics AG. (6/22/23). "Press Release: Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [5] Memo Therapeutics AG. (5/2/23). "Press Release: Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [6] Memo Therapeutics AG. (1/24/23). "Press Release: Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients". Schlieren....
- [7] Memo Therapeutics AG. (11/1/22). "Press Release: Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets". Schlieren....
- [8] Verve Capital Partners AG (Verve Ventures). (6/24/22). "Press Release: Verve Ventures Launches Investment Fund to Support Portfolio Companies"....
- [9] Memo Therapeutics AG. (2/26/22). "Press Release: Memo Therapeutics AG Closes Series B Financing at CHF37 Million Following Oversubscribed CHF23 Million Extension". Schlieren....
- [10] Memo Therapeutics AG. (12/13/21). "Press Release: Memo Therapeutics AG to Receive CHF 10.5 Million from Swiss Federal Funding Programme to Clinically Develop SARS-CoV-2 Antibody Against COVID-19". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top